GPBAR1 and myeloid sarcoma: In experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, TUDCA treatment mitigated astrocytic neuroinflammation by regulating TGR5-mediated AKT/NFκB signaling pathway, thus alleviating EAE [39].